Mersana Therapeutics, Inc. (MRSN) EPS Estimated At $-0.50

January 13, 2018 - By Henry Gaston

 Mersana Therapeutics, Inc. (MRSN) EPS Estimated At $ 0.50

Analysts expect Mersana Therapeutics, Inc. (NASDAQ:MRSN) to report $-0.50 EPS on February, 8.After having $-0.35 EPS previously, Mersana Therapeutics, Inc.’s analysts see 42.86 % EPS growth. The stock decreased 2.89% or $0.46 during the last trading session, reaching $15.44. About 40,813 shares traded. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Ratings Coverage

Among 3 analysts covering Mersana Therapeutics Inc (NASDAQ:MRSN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mersana Therapeutics Inc has $2300 highest and $2300 lowest target. $23’s average target is 48.96% above currents $15.44 stock price. Mersana Therapeutics Inc had 3 analyst reports since July 24, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Monday, July 24 by Cowen & Co. The stock of Mersana Therapeutics, Inc. (NASDAQ:MRSN) has “Buy” rating given on Monday, July 24 by J.P. Morgan. The stock has “Buy” rating by Leerink Swann on Monday, July 24.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $351.31 million. The firm develops immune conjugate therapies to create drugs that enhance patients?? lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

More notable recent Mersana Therapeutics, Inc. (NASDAQ:MRSN) news were published by: which released: “Mersana Therapeutics Added to NASDAQ Biotechnology Index” on December 15, 2017, also with their article: “Mersana Therapeutics Inc.” published on June 05, 2017, published: “Mersana Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference” on December 20, 2017. More interesting news about Mersana Therapeutics, Inc. (NASDAQ:MRSN) were released by: and their article: “Mersana Therapeutics completes $75 million IPO” published on June 28, 2017 as well as‘s news article titled: “Mersana Therapeutics (MRSN) Reports First Patient Dosed with XMT-1536 in Phase …” with publication date: December 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.